Who is the CEO of Odonate Therapeutics, Inc.?

The CEO of Odonate Therapeutics, Inc. is Kevin Tang.

What industry does Odonate Therapeutics, Inc. belong to?

Odonate Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector.

Where is Odonate Therapeutics, Inc. headquartered?

Odonate Therapeutics, Inc. is headquartered at 4747 Executive Dr Ste 510, San Diego, CA, 10016, US.

What is the IPO date of Odonate Therapeutics, Inc.?

Odonate Therapeutics, Inc. went public on December 7, 2017.

How many employees does Odonate Therapeutics, Inc. have?

Odonate Therapeutics, Inc. has approximately 137 full-time employees.

Odonate Therapeutics, Inc.

ODT•NASDAQ

Healthcare

Biotechnology

$1.12

$-0.05(-4.27%)

Odonate Therapeutics, Inc. (ODT) Company Profile & Overview

Explore Odonate Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Odonate Therapeutics, Inc. (ODT) Company Profile & Overview

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

SectorHealthcare

IndustryBiotechnology

CEOKevin Tang

Contact Information

https://www.odonate.com

18582003830

4747 Executive Dr Ste 510, San Diego, CA, 10016

Company Facts

137 Employees

IPO DateDec 7, 2017

CountryUS

Frequently Asked Questions

;